"Sulfadoxine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A long acting sulfonamide that is used, usually in combination with other drugs, for respiratory, urinary tract, and malarial infections.
| Descriptor ID |
D013413
|
| MeSH Number(s) |
D02.065.884.725.765 D02.092.146.807.765 D02.886.590.700.725.765
|
| Concept/Terms |
Sulfadoxine- Sulfadoxine
- Sulphormetoxin
- Sulphorthodimethoxine
- Sulformetoxine
- Sulformethoxine
- Sulforthomidine
|
Below are MeSH descriptors whose meaning is more general than "Sulfadoxine".
Below are MeSH descriptors whose meaning is more specific than "Sulfadoxine".
This graph shows the total number of publications written about "Sulfadoxine" by people in this website by year, and whether "Sulfadoxine" was a major or minor topic of these publications.
View timeline visualization
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 1 | 1 |
| 2001 | 1 | 1 | 2 |
| 2002 | 1 | 0 | 1 |
| 2003 | 3 | 1 | 4 |
| 2004 | 2 | 1 | 3 |
| 2005 | 2 | 1 | 3 |
| 2006 | 5 | 3 | 8 |
| 2007 | 3 | 2 | 5 |
| 2008 | 2 | 3 | 5 |
| 2009 | 4 | 3 | 7 |
| 2010 | 2 | 4 | 6 |
| 2011 | 1 | 2 | 3 |
| 2012 | 1 | 1 | 2 |
| 2013 | 2 | 0 | 2 |
| 2014 | 1 | 3 | 4 |
| 2015 | 2 | 1 | 3 |
| 2016 | 1 | 2 | 3 |
| 2017 | 1 | 2 | 3 |
| 2018 | 2 | 2 | 4 |
| 2019 | 1 | 2 | 3 |
| 2020 | 2 | 7 | 9 |
| 2021 | 1 | 3 | 4 |
| 2023 | 0 | 2 | 2 |
| 2024 | 1 | 2 | 3 |
| 2025 | 1 | 1 | 2 |
Below are the most recent publications written about "Sulfadoxine" by people in Profiles.
-
Dihydroartemisinin-piperaquine plus sulfadoxine-pyrimethamine versus either drug alone for intermittent preventive treatment of malaria in pregnancy: A double-blind, randomized, controlled phase 3 trial from Uganda. PLoS Med. 2025 Sep; 22(9):e1004582.
-
Antimalarial drug resistance and population structure of Plasmodium falciparum in Mozambique using genomic surveillance at health facilities in 2021 and 2022. Sci Rep. 2025 Aug 11; 15(1):29335.
-
Intermittent preventive treatment for malaria in pregnancy and infant growth: a mediation analysis of a randomised trial. EBioMedicine. 2024 Nov; 109:105397.
-
Drug-Drug Interaction Between Dihydroartemisinin-Piperaquine and Sulfadoxine-Pyrimethamine During Malaria Chemoprevention in Pregnant Women. Clin Pharmacol Ther. 2025 Feb; 117(2):506-514.
-
Determination of sulfadoxine and pyrimethamine in microvolume human plasma using ultra high performance liquid chromatography-tandam mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2024 Feb 15; 1234:124030.
-
Seasonal Malaria Chemoprevention Drug Levels and Drug Resistance Markers in Children With or Without Malaria in Burkina Faso: A Case-Control Study. J Infect Dis. 2023 10 03; 228(7):926-935.
-
Effect of Malaria and Malaria Chemoprevention Regimens in Pregnancy and Childhood on Neurodevelopmental and Behavioral Outcomes in Children at 12, 24, and 36 Months: A Randomized Clinical Trial. Clin Infect Dis. 2023 02 18; 76(4):600-608.
-
A novel CRISPR-based malaria diagnostic capable of Plasmodium detection, species differentiation, and drug-resistance genotyping. EBioMedicine. 2021 Jun; 68:103415.
-
Malaria PK/PD and the Role Pharmacometrics Can Play in the Global Health Arena: Malaria Treatment Regimens for Vulnerable Populations. Clin Pharmacol Ther. 2021 10; 110(4):926-940.
-
Polymorphisms in Plasmodium falciparum dihydropteroate synthetase and dihydrofolate reductase genes in Nigerian children with uncomplicated malaria using high-resolution melting technique. Sci Rep. 2021 01 12; 11(1):471.